Integra LifeSciences Holdings Corp. - Q1 2026 Filing Summary
Business Context and Reporting Period
This summary covers the unaudited Form 10-Q for Integra LifeSciences Holdings Corporation for the quarterly period ended March 31, 2026. Integra is a global medical technology company operating in two reportable segments: Specialty Surgery (Neurosurgery, Instruments, ENT) and Tissue Reconstruction (Wound Reconstruction, Private Label). The company continues to navigate regulatory remediation efforts, specifically regarding FDA quality system issues at its Boston facility, while transitioning manufacturing to a new facility in Braintree, Massachusetts.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $391.9 million | $382.7 million |
| Gross Margin | $217.0 million (55.4%) | $194.4 million (50.8%) |
| Operating Income | $11.5 million | $(15.5) million |
| Net Loss | $(4.6) million | $(25.3) million |
| Diluted EPS | $(0.06) | $(0.33) |
| Operating Cash Flow | $9.8 million | $(11.3) million |
| Cash & Equivalents | $236.8 million | $239.1 million |
| Total Debt (Carrying Value) | $1.87 billion | $1.86 billion |
Material Changes vs. Prior Period
- Profitability Improvement: The company returned to operating profitability ($11.5M) compared to an operating loss in the prior year, driven by reduced costs related to quality remediation and the Braintree transition.
- Revenue Growth: Total revenue increased 2.4% year-over-year. Specialty Surgery grew 1% (driven by Neurosurgery), while Tissue Reconstruction grew 7% (driven by Integra Skin and DuraSorb recovery).
- Margin Expansion: Gross margin percentage improved to 55.4% from 50.8%, attributed to higher revenues and lower remediation costs.
- Tax Rate Volatility: The effective tax rate was (91.7)% in Q1 2026 compared to 15.8% in Q1 2025. The negative rate was primarily due to a $2.9 million tax expense related to a shortfall in stock-based compensation benefits.
- Interest Expense: Interest expense increased by $3.7 million due to higher rates on the revolving credit facility following the repayment of the 0.5% Convertible Senior Notes in August 2025.
Outlook, Risks, and Unusual Items
- Tariff Refund Receivable: Following a U.S. Supreme Court ruling invalidating certain IEEPA tariffs, the company recognized an $18.7 million receivable for tariff refunds. $15.3 million of this relates to costs that would have been expensed in the current year.
- Restructuring: The company is executing a restructuring initiative approved in Q4 2025 with estimated total costs of $12.3 million. $3.8 million was incurred in Q1 2026.
- Regulatory Status: The company is actively remediating quality system issues identified by the FDA in 2024. The Braintree facility is expected to be operational in June 2026. PMA approvals for SurgiMend and DuraSorb are anticipated in 2027.
- Debt Covenants: The company is in compliance with its Senior Credit Facility covenants. The Consolidated Total Leverage Ratio was 4.12x, well below the 5.00x requirement for the quarter.
- Legal Proceedings: The company successfully won an arbitration regarding ACell earnout consideration in April 2026. Securities class action litigation regarding the Boston facility remains pending, with motions to dismiss filed.
Investor Verification Checklist
- Tariff Refund Realization: Verify the timeline and probability of receiving the $18.7 million IEEPA tariff refund from U.S. Customs and Border Protection.
- Braintree Facility Timeline: Monitor the operational readiness of the Braintree facility scheduled for June 2026 and its impact on SurgiMend/DuraSorb revenue.
- Regulatory Resolution: Track FDA responses to the 2024 Warning Letter and Form 483s to ensure no further restrictions on Class III device approvals.
- Debt Servicing: Assess the impact of rising interest rates on the $1.87 billion debt load, particularly as the covenant relief period ends in late 2026.
- Restructuring Execution: Confirm that the remaining $8.5 million of restructuring costs are incurred as planned and yield the expected operational efficiencies.